Thrivent Financial for Lutherans
MRSN

Thrivent Financial for Lutherans’s Mersana Therapeutics MRSN Stock Holding History

Thrivent Financial for Lutherans’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,323
Closed -$191K – 2476
2023
Q2 		$191K Sell
2,323
-114
-5% -$16.7K ﹤0.01% 2411
2023
Q1 		$250K Hold
2,437
– – ﹤0.01% 2336
2022
Q4 		$357K Buy
+2,437
New +$412K ﹤0.01% 2216
2021
Q1 		– Sell
-1,301
Closed -$865K – 2562
2020
Q4 		$865K Buy
1,301
+370
+40% +$206K ﹤0.01% 1847
2020
Q3 		$433K Sell
931
-381
-29% -$193K ﹤0.01% 2039
2020
Q2 		$768K Buy
1,312
+370
+39% +$126K ﹤0.01% 1675
2020
Q1 		$137K Buy
+942
New +$165K ﹤0.01% 2182

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.34B AUM 204.53% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $50.9B AUM 42.89% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $849M AUM 470.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.71B AUM 374.45% 1-Year Est. Return